CHROMagar™ Acinetobacter powder and supplement

Product information

Especially, Acinetobacter baumannii is becoming a major hospital-acquired infection issue because of its often multi-drug resistance (MDR : resistance to C3G, quinolones, carbapenem etc). This contributes to the increase of morbidity and mortality. Active surveillance is necessary to control its spread in the facilities, to reduce the risk of cross-contamination, and to identify the carriers. Rapid identification of patients that are colonized with Acinetobacter would lead to infection control practices aimed at preventing spread of the organisms. Detection of A. baumannii from traditional culture media might be a difficult and tedious task due to the abundance of background flora found in collected specimens, especially when using media based on differentiation by the lactose/non-lactose fermentation ability. To overcome these difficulties, CHROMagar Acinetobacter was designed as a highly selective medium, allowing the growth of Acinetobacter in conspiciously red colonies, after overnight incubation.